<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653702</url>
  </required_header>
  <id_info>
    <org_study_id>P00027566</org_study_id>
    <nct_id>NCT03653702</nct_id>
  </id_info>
  <brief_title>Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)</brief_title>
  <official_title>Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study the investigators want to study a safe, radiation-free technique known
      as contrast-enhanced ultrasound that may improve the ability to diagnose or evaluate renal
      scarring compared to regular ultrasound. This technique requires injection into a vein of a
      small amount of contrast material called Lumason. Contrast material is a type of dye that
      helps the investigators image the structures in the body more clearly. If this technique is
      successful, the need for DMSA studies may be avoided to diagnose or evaluate kidney scarring.
      DMSA is a more expensive test, causes radiation exposure, may require sedation and/or
      injection of contrast agents with the potential to cause allergic reactions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of CEUS result and comparison to DMSA</measure>
    <time_frame>3 months after final participant completes participation</time_frame>
    <description>DMSA will be used as gold standard to evaluate CEUS test performance. Sensitivity and specificity of CEUS renal scarring detection will be calculated accordingly. Bivariate and multivariate analyses will be completed to compare patient characteristics between those with good and poor CEUS performance to investigate if CEUS performs better in patients with specific covariates</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Vesico-Ureteral Reflux</condition>
  <arm_group>
    <arm_group_label>Contrast Enhanced Ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo a contrast enhanced ultrasound (CEUS) using Lumason</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumason</intervention_name>
    <description>Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection</description>
    <arm_group_label>Contrast Enhanced Ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients older than or equal to 6 months and less than or equal to 35 years old and
             scheduled for Boston Children's Hospital (BCH) DMSA scan to evaluate renal function
             and/or renal scarring

        Exclusion Criteria:

          -  patients with significant congenital renal anatomical abnormalities including
             horseshoe kidney, kidney malrotation, and multicystic dysplastic kidney (MCDK).
             Patients with severe cardio-pulmonary diseases will also be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alyssia Venna</last_name>
    <phone>617-919-6352</phone>
    <email>alyssia.venna@childrens.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Lee</last_name>
    <phone>617-919-2637</phone>
    <email>james.lee@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian McCarthy</last_name>
      <phone>617-355-4720</phone>
      <email>Ian.McCarthy@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>James Lee</last_name>
      <phone>617-919-2637</phone>
      <email>James.Lee@childrens.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Richard Lee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vesico-Ureteral Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

